Christine J. Saoud

Array ( [id] => 14864845 [patent_doc_number] => 20190282664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => METHODS FOR STIMULATION OF APPETITE AND INCREASE IN WEIGHT BY ADMINISTRATION OF ASPROSIN [patent_app_type] => utility [patent_app_number] => 16/424321 [patent_app_country] => US [patent_app_date] => 2019-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16424321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839517 [patent_doc_number] => 20210147529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => PHARMACEUTICAL COMPOSITION FOR SUPPRESSING ATRIAL FIBRILLATION HAVING AS ACTIVE INGREDIENT ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF [patent_app_type] => utility [patent_app_number] => 17/055406 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19120038 [patent_doc_number] => 11963999 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant FC fusion proteins [patent_app_type] => utility [patent_app_number] => 16/407813 [patent_app_country] => US [patent_app_date] => 2019-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 30 [patent_no_of_words] => 22720 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16407813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885452 [patent_doc_number] => 20210171647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => FULLY HUMAN ANTIBODIES AGAINST OX40, METHOD FOR PREPARING THE SAME, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/054700 [patent_app_country] => US [patent_app_date] => 2019-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28164 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807869 [patent_doc_number] => 20210130422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => Novel Fusion Protein, and Pharmaceutical Composition For Preventing Or Treating Cancer, Containing Same [patent_app_type] => utility [patent_app_number] => 17/050816 [patent_app_country] => US [patent_app_date] => 2019-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715633 [patent_doc_number] => 20190248880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => CARTILAGE TARGETING AGENTS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 16/391101 [patent_app_country] => US [patent_app_date] => 2019-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16391101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16991841 [patent_doc_number] => 20210230261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => BUFFERED FORMULATIONS OF BEVACIZUMAB FOR USE OF TREATING DISEASES [patent_app_type] => utility [patent_app_number] => 17/048107 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17048107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17922846 [patent_doc_number] => 11466079 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => C-terminal antibody variants [patent_app_type] => utility [patent_app_number] => 16/971590 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 15699 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836089 [patent_doc_number] => 20190276445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => BLOCKERS OF THE GROWTH HORMONE RECEPTOR IN DISEASE PREVENTION AND TREATMENT [patent_app_type] => utility [patent_app_number] => 16/366662 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16366662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17308341 [patent_doc_number] => 11209444 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Treatment for age-related macular degeneration (AMD) and pathogenic ocular neovascularization [patent_app_type] => utility [patent_app_number] => 16/363886 [patent_app_country] => US [patent_app_date] => 2019-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 28 [patent_no_of_words] => 23457 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16363886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18302069 [patent_doc_number] => 11623960 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Dual-function antibodies targeting VEGFR2 and VEGFR3 [patent_app_type] => utility [patent_app_number] => 16/982361 [patent_app_country] => US [patent_app_date] => 2019-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9912 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16982361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18685198 [patent_doc_number] => 11780916 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof [patent_app_type] => utility [patent_app_number] => 16/982443 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 24248 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16982443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621832 [patent_doc_number] => 20210040485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => Elimination or Neutralization of Endogenous High Molecular Weight FGF-2 Increases Cardiac Resistance to Doxorubicin-Induced Damage [patent_app_type] => utility [patent_app_number] => 16/977614 [patent_app_country] => US [patent_app_date] => 2019-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16977614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17250101 [patent_doc_number] => 11185570 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides [patent_app_type] => utility [patent_app_number] => 16/287342 [patent_app_country] => US [patent_app_date] => 2019-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 13 [patent_no_of_words] => 44955 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16287342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16259982 [patent_doc_number] => 10751391 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid [patent_app_type] => utility [patent_app_number] => 16/285986 [patent_app_country] => US [patent_app_date] => 2019-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 50 [patent_no_of_words] => 112847 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16285986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14439119 [patent_doc_number] => 20190177432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/284774 [patent_app_country] => US [patent_app_date] => 2019-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16284774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407183 [patent_doc_number] => 11248052 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Antigen binding proteins that bind to a complex comprising b-Klotho and an FGF receptor [patent_app_type] => utility [patent_app_number] => 16/282834 [patent_app_country] => US [patent_app_date] => 2019-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 70879 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16282834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14435647 [patent_doc_number] => 20190175695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Modulating Bile Acid Homeostasis in a Subject Having Cirrhosis [patent_app_type] => utility [patent_app_number] => 16/282058 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16282058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14435645 [patent_doc_number] => 20190175694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Liver Fibrosis [patent_app_type] => utility [patent_app_number] => 16/282029 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16282029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14435641 [patent_doc_number] => 20190175692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Nonalcoholic Fatty Liver Disease [patent_app_type] => utility [patent_app_number] => 16/281967 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33515 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16281967 [rel_patent_id] =>[rel_patent_doc_number] =>)